We tried, myeloma world, but we couldn't come up with a short title for today's report.

There were just too many words needed to describe the three research articles that we plan to review with you in this edition of Myeloma Morning.

First, we have an important new study out of Spain that in­ves­ti­gates the sig­nif­i­cance of Bence Jones protein in smol­der­ing multiple myeloma patients.

Next, we turn to a study by researchers in Japan. They in­ves­ti­gate different methods for measuring …

A pleasant Tuesday to you, myeloma world.

We hope your week has started well. We been away for longer than ex­pec­ted, work­ing through some of the more technical details of the articles we discuss in today's Myeloma Morning.

Most of today's report focuses on two research articles that were published last week. Both articles were published in the journal Blood, and both are valuable contributions to what we know about multiple myeloma. As a result, we devote quite a bit …

A happy Saturday to you, myeloma world.

We hope your weekend has gotten off to an excellent start.

Today's edition of Myeloma Morning focuses primarily on a study that was included in yesterday's list of new myeloma-related research. The study summarizes trends in allogeneic (donor) stem cell transplantation in Europe over the last two decades.

Although the study focuses on European trends, we believe it should be of interest to Beacon readers regardless where they may be. With the global …

We're very glad to see you again, myeloma world.

Myeloma Morning was on brief hiatus while we helped with the Beacon's article about the recently published Ninlaro (ixazomib) clinical trial results.

Now that the Ninlaro article has been published, however, it's time to get back to normal Myeloma Morning business.

And there's a lot of it. In fact, there are almost 20 items in the list of new myeloma research at …

Hello, myeloma world. We hope your week has started well.

We have one main item on the agenda for today's edition of Myeloma Morning.

In particular, we want to discuss a topic that is the focus of the only article in our daily list of new myeloma-related research publications, included at the end of this report.

The topic of that article is monoclonal gammopathy of renal significance (MGRS).

Now, most Beacon readers probably have heard of monoclonal …

A happy Sunday to you, myeloma world.

We hope you have been having a pleasant weekend. We've been looking over some of the new multiple myeloma research published in the past few days, and there are two studies we thought we would discuss with you in today's Myeloma Morning.

The first is a case report involving a myeloma patient who has been in remission for more than 15 years. This remission, it seems, may be an unexpected …

A happy Saturday to you, myeloma world.

We have some good news to report today. It also is im­por­tant news related to Darzalex (dara­tu­mu­mab).

Some addi­tional clin­i­cal trial results related to Darzalex were made public earlier this week, but they have not received much attention.

The new results show that adding Darzalex to Velcade (bor­tez­o­mib) and dexa­metha­sone sub­stan­tially – some might even say dramatically – extends pro­gres­sion-free survival in re­lapsed multiple myeloma patients.

The new results expand …